Search
for

    Glossary5α-reductase inhibitory activity

    blocks enzyme converting testosterone to hair-loss-linked DHT

    5α-reductase inhibitory activity refers to the ability of a substance to block the action of the enzyme 5α-reductase. This enzyme converts testosterone into dihydrotestosterone (DHT), a hormone linked to hair loss and conditions like benign prostatic hyperplasia. By inhibiting 5α-reductase, these substances can help reduce DHT levels, potentially preventing hair loss and treating related conditions.

    Related Terms

    Learn

    2 / 2 results

      learn Dutasteride

      Heavy duty finasteride that comes with higher risks, but scalp injections seem safe and are gaining popularity

    Research

    5 / 364 results

    Community Join

    5 / 1000+ results

      community DHT and 5AR respect post, it's importance within the brain

      in Research/Science  111 upvotes 1 year ago
      The conversation discusses whether to use finasteride for hair loss, considering its role in inhibiting DHT and 5AR, which can affect brain function and mood. Some users report anxiety and depression from finasteride, while others do not experience these side effects and emphasize the importance of DHT for brain and prostate health.

      community Finasteride does deplete important nuero-active steroids

      in Research/Science  9 upvotes 2 years ago
      Finasteride can reduce neuroactive steroids, causing side effects like depression, anxiety, and sexual dysfunction. Some users experience persistent symptoms after stopping finasteride, while others use alternative treatments like topical solutions.
      FCE 28260: A Forgotten 5α-Reductase Inhibitor

      community FCE 28260: A Forgotten 5α-Reductase Inhibitor

      in Research  330 upvotes 1 year ago
      FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.